GoAI
Get started
Atrium Therapeutics, Inc. logo

Atrium Therapeutics, Inc.

RNA

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$13.20

−$0.28 · -2.08%

Aug 21, 4:00 PM ET

RNA company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

51

Fair Value

Momentum

37

Weakening

Sentiment

62

Bullish

Risk resilience

58

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Kathleen Gallagher
Listed since
Feb 27, 2026
Employees
511

Market position

Day range

Current $13.20

52-week range

Current $13.20

Open
$13.53
Previous close
$13.48
Volume
180.68K
0.81× average
Average volume
222.52K
Average daily volume
Market cap
225.79M USD
Beta
0.37
Market reference 1
50-day average
$12.4742
+5.82% above average
200-day average
$13.0309
+1.30% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-3.43×
P/B (TTM)
1.05×
P/S (TTM)
9.61×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
97.90%
Operating margin
-374.21%
Net margin
-361.26%

Financial health

Debt / equity
0.01×

Earnings

EPS beat rate
64%
7 beats, 3 misses, 1 met estimate
Average EPS surprise
+9.50%
11 comparable reports
Latest EPS result
-1.18
Estimate -1.42 · Beat by 16.90%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.55-0.86-1.17-1.48Q3 '24BeatQ4 '24BeatQ1 '25MissQ2 '25MetQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q3 2024, reported Aug 9, 2024: actual -0.65, estimate -0.79, surprise +17.72%, Beat. Q4 2024, reported Nov 7, 2024: actual -0.65, estimate -0.71, surprise +8.45%, Beat. Q1 2025, reported Feb 27, 2025: actual -0.8, estimate -0.79, surprise -1.27%, Miss. Q2 2025, reported May 8, 2025: actual -0.9, estimate -0.9, surprise 0.00%, Met estimate. Q1 2026, reported Feb 26, 2026: actual -0.61, estimate -1.24, surprise +50.81%, Beat. Q2 2026, reported May 14, 2026: actual -0.97, estimate -1.05, surprise +7.62%, Beat. Q3 2026, reported Aug 13, 2026: actual -1.18, estimate -1.42, surprise +16.90%, Beat. Q4 2026, reported Nov 12, 2026: actual —, estimate -0.866, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates21.15M14.29M7.43M566.67KQ3 '24EstimateQ4 '24EstimateQ1 '25EstimateQ2 '25EstimateQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q3 2024, reported Aug 9, 2024: actual —, estimate 2.63M USD, surprise —, Comparison unavailable. Q4 2024, reported Nov 7, 2024: actual —, estimate 4.07M USD, surprise —, Comparison unavailable. Q1 2025, reported Feb 27, 2025: actual —, estimate 1.63M USD, surprise —, Comparison unavailable. Q2 2025, reported May 8, 2025: actual —, estimate 2.37M USD, surprise —, Comparison unavailable. Q1 2026, reported Feb 26, 2026: actual 2.1M USD, estimate 1.98M USD, surprise +5.98%, Beat. Q2 2026, reported May 14, 2026: actual 19.64M USD, estimate 2M USD, surprise +881.75%, Beat. Q3 2026, reported Aug 13, 2026: actual 3M USD, estimate 666.67K USD, surprise +350.60%, Beat. Q4 2026, reported Nov 12, 2026: actual —, estimate 15M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$25.00

89.39% upside
Past 12 months12-month forecastHigh $25.00Average $25.00Low $25.00

Rating distribution

16 ratings
Strong buy00%
Buy850%
Hold850%
Sell00%
Strong sell00%

RNA peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding RNA

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
5.88M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
5.01M
Weight
0.01%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
2.14M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
1.19M
Weight
0.01%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
1M
Weight
0.00%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.83+0.52%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
917.85K
Weight
0.01%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
658.07K
Weight
0.04%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
550.13K
Weight
0.00%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$224.81+0.45%

Continue in GoAI

Research RNA

research.disclaimer